Tourmaline Bio Inc (TRML) - News Archive

The pharmaceutical landscape is continuously evolving, and companies like Tourmaline Bio exemplify this dynamic environment. In their second quarter of 2025, Tourmaline Bio released a comprehensive financial report high...

Spotlight on Cardiovascular Inflammation: Tourmaline Bio’s Strategic Advances Revealed at Investor Day In an exciting confluence of innovation and strategy, Tourmaline Bio recently showcased its pioneering focus on card...

Tourmaline Bio, a pioneering company in developing therapeutics for cardiovascular health, recently unveiled the design of its Phase 2 TRANQUILITY study at the esteemed American Society of Preventive Cardiology (ASPC) C...

Emerging Therapeutic Frontiers: Tourmaline Bio s TOUR006 as a Potential Game-Changer in Cardiovascular Disease Management CSIMarket.com The initiation of Phase 2 clinical trials for TOUR006 marks a significant milestone...

Tourmaline Bio Announces Successful Pricing of Public Offering of Common StockTourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company specializing in the development of transformative medicines fo...

Tourmaline Bio Inc., a leading clinical biotechnology company, has announced the launch of a proposed underwritten public offering of its common stock. The company aims to develop innovative medicines that can significa...

In a recent development, Tourmaline Bio has announced a series of exciting milestones for the clinical development of their investigational compound, TOUR006. With cutting-edge potential as a long-acting subcutaneous in...